135 related articles for article (PubMed ID: 34593419)
1. The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model.
Wu NF; Yamamoto J; Aoki Y; Masaki N; Samonte C; Wu J; Bouvet M; Hoffman RM
Anticancer Res; 2021 Oct; 41(10):4715-4718. PubMed ID: 34593419
[TBL] [Abstract][Full Text] [Related]
2. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
[TBL] [Abstract][Full Text] [Related]
3. Oral-recombinant Methioninase Lowers the Effective Dose and Eliminates Toxicity of Cisplatinum for Primary Osteosarcoma of the Mammary Gland in a Patient-derived Orthotopic Xenograft Mouse Model.
Masaki N; Han Q; Wu NF; Samonte C; Wu J; Hozumi C; Obara K; Kubota Y; Aoki Y; Miyazaki J; Hoffman RM
In Vivo; 2022; 36(6):2598-2603. PubMed ID: 36309364
[TBL] [Abstract][Full Text] [Related]
4. A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatinum-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
Igarashi K; Kawaguchi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Higuchi T; Taniguchi Y; Yonezawa H; Araki Y; Morinaga S; Misra S; Nelson SD; Dry SM; Li Y; Odani A; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(3):217-223. PubMed ID: 32345663
[TBL] [Abstract][Full Text] [Related]
5. Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic.
Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Li S; Han Q; Tan Y; Zhao M; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
Cell Cycle; 2018; 17(6):801-809. PubMed ID: 29374999
[TBL] [Abstract][Full Text] [Related]
6. Osteosarcoma of the Breast in a Patient Derived Orthotopic Xenograft (PDOX) Mouse Model Is Arrested by both Cisplatinum and Eribulin.
Masaki N; Wu NF; Aoki Y; Yamamoto J; Miyazaki J; Hoffman RM
In Vivo; 2021; 35(6):3107-3110. PubMed ID: 34697141
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Anticancer Res; 2019 Aug; 39(8):4079-4084. PubMed ID: 31366491
[TBL] [Abstract][Full Text] [Related]
8. Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model.
Higuchi T; Miyake K; Oshiro H; Sugisawa N; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biochem Biophys Res Commun; 2019 May; 513(2):326-331. PubMed ID: 30955860
[TBL] [Abstract][Full Text] [Related]
9. Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma.
Higuchi T; Oshiro H; Miyake K; Sugisawa N; Han Q; Tan Y; Park J; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Chawla SP; Singh SR; Tsuchiya H; Hoffman RM
Anticancer Res; 2019 Sep; 39(9):4653-4657. PubMed ID: 31519563
[TBL] [Abstract][Full Text] [Related]
10. Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
Anticancer Res; 2021 Jul; 41(7):3287-3292. PubMed ID: 34230123
[TBL] [Abstract][Full Text] [Related]
11. Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Belt P; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Anticancer Res; 2019 Sep; 39(9):4781-4786. PubMed ID: 31519579
[TBL] [Abstract][Full Text] [Related]
12. Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
Kiyuna T; Tome Y; Miyake K; Murakami T; Oshiro H; Igarashi K; Kawaguchi K; Hsu J; Singh M; Li Y; Nelson S; Bouvet M; Singh SR; Kanaya F; Hoffman RM
Anticancer Res; 2019 Sep; 39(9):4775-4779. PubMed ID: 31519578
[TBL] [Abstract][Full Text] [Related]
13. Oral-recombinant Methioninase in Combination With Rapamycin Eradicates Osteosarcoma of the Breast in a Patient-derived Orthotopic Xenograft Mouse Model.
Masaki N; Han Q; Samonte C; Wu NF; Hozumi C; Wu J; Obara K; Kubota Y; Aoki Y; Bouvet M; Hoffman RM
Anticancer Res; 2022 Nov; 42(11):5217-5222. PubMed ID: 36288875
[TBL] [Abstract][Full Text] [Related]
14. The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Transl Oncol; 2019 Sep; 12(9):1257-1263. PubMed ID: 31299622
[TBL] [Abstract][Full Text] [Related]
15. Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Kubota Y; Bouvet M; Nishida K; Hoffman RM
Anticancer Res; 2022 Feb; 42(2):731-737. PubMed ID: 35093871
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biomed Pharmacother; 2019 Oct; 118():109356. PubMed ID: 31545293
[TBL] [Abstract][Full Text] [Related]
17. Cervical Cancer Patient-Derived Orthotopic Xenograft (PDOX) Is Sensitive to Cisplatinum and Resistant to Nab-paclitaxel.
Murakami T; Murata T; Kawaguchi K; Kiyuna T; Igarashi K; Hwang HK; Hiroshima Y; Hozumi C; Komatsu S; Kikuchi T; Lwin TM; Delong JC; Miyake K; Zhang Y; Tanaka K; Bouvet M; Endo I; Hoffman RM
Anticancer Res; 2017 Jan; 37(1):61-65. PubMed ID: 28011474
[TBL] [Abstract][Full Text] [Related]
18. An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model.
Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
Sci Rep; 2021 Apr; 11(1):8583. PubMed ID: 33883561
[TBL] [Abstract][Full Text] [Related]
19. Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma.
Igarashi K; Kawaguchi K; Li S; Han Q; Tan Y; Murakami T; Kiyuna T; Miyake K; Miyake M; Singh AS; Eckardt MA; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Singh SR; Eilber FC; Hoffman RM
Cancer Lett; 2018 Mar; 417():168-173. PubMed ID: 29306021
[TBL] [Abstract][Full Text] [Related]
20. A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model.
Kiyuna T; Tome Y; Murakami T; Miyake K; Igarashi K; Kawaguchi K; Oshiro H; Higuchi T; Miyake M; Sugisawa N; Zhang Z; Razmjooei S; Wangsiricharoen S; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Eckardt MA; Singh AS; Chawla S; Kanaya F; Eilber FC; Singh SR; Zhao M; Hoffman RM
Biochem Biophys Res Commun; 2018 Nov; 505(3):733-739. PubMed ID: 30292411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]